Garrido Marques, Antonio
Rubinacci, Simone
Malaspinas, Anna-Sapfo
Delaneau, Olivier
Sousa da Mota, Bárbara
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (PP00P3_176977, PP00P3_176977, PCEGP3_181251, PP00P3_176977, PP00P3_176977)
European Research Council (679330, 679330, 679330)
Article History
Received: 19 December 2023
Accepted: 8 March 2024
First Online: 14 March 2024
Competing interests
: Olivier Delaneau is a current employee of Regeneron Genetics Center which is a subsidiary of Regeneron Pharmaceuticals. The remaining authors declare no conflicts of interests.